Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2018 Publisher: Douglas Pharmaceuticals Ltd, PO Box 45 027, Auckland 0651, New Zealand, Phone: (09) 835 0660
BICALOX film-coated tablet, 50 mg.
| Pharmaceutical Form |
|---|
|
BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with ‘BC 50’ on one face and plain on the other. |
Each BICALOX tablet contains bicalutamide 50 mg.
Excipient(s) with known effect: BICALOX tablets contain lactose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Bicalutamide |
Bicalutamide is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. |
| List of Excipients |
|---|
|
Lactose, sodium starch glycollate, povidone, magnesium stearate, opadry white Y-1-7000. |
PVC/PVdC-Aluminium blisters: 28, 30, 56, 98 tablets.
HDPE bottle: 100, 500 tablets.
Not all pack types or sizes may be marketed.
Douglas Pharmaceuticals Ltd, PO Box 45 027, Auckland 0651, New Zealand, Phone: (09) 835 0660
24 April 2008
| Drug | Countries | |
|---|---|---|
| BICALOX | Australia, Hong Kong, New Zealand, Singapore, Tunisia, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
